Catalog No.
Product Name
Application
Product Information
Citations
-
BCR-ABL Inhibitor
BCR-ABL-IN-4 is a potent inhibitor of the BCR-ABL oncogene, exhibiting significant anticancer activity. It effectively suppresses the proliferation of cancer cells, demonstrating IC50 values of 0.67 nM in K562 cells and 16 nM in BCR-ABL T315I transfected Ba/F3 cells. This compound is valuable for research applications focused on targeted cancer therapies and understanding resistance mechanisms in BCR-ABL positive malignancies. -
BCR-ABL-T315I Mutation Inhibitor
GNF-6 is a potent inhibitor of the BCR-ABL-T315I mutation, acting primarily as an ATP-competitive inhibitor. It demonstrates inhibitory activity with IC50 values of 0.25 μM for c-ABL-T334I, 0.09 μM for BCR-ABL, and 0.590 μM for the BCR-ABL-T315I variant. By disrupting the assembly of the hydrophobic spine, GNF-6 stabilizes the kinase in an inactive 'DFG-out' conformation, making it a valuable tool for research on resistance mechanisms in chronic myeloid leukemia (CML) and targeted therapeutic strategies. -
BCR-ABL PROTAC Degrader
Phe-PEG1-Dasa is a BCR-ABL PROTAC degrader, demonstrating a DC50 value of 1.56 nM. This compound utilizes phenylalanine as the E3 ligase ligand and triggers the N-end rule pathway to facilitate the degradation of target proteins. Phe-PEG1-Dasa effectively suppresses the proliferation of K562 leukemia cells, making it a valuable tool for research into leukemia treatment strategies. -
ABL Inhibitor
PonatiLink-1-24 is an inhibitor of the Abelson murine leukemia virus (ABL) enzyme. This compound demonstrates significant biological activity by selectively inhibiting ABL kinase activity, which is vital in various malignancies. It is particularly useful in studying cancer cell signaling pathways and the development of targeted therapies for ABL-related disorders. -
Scr/ABL Inhibitor
AP-24226 is a selective inhibitor of the non-receptor tyrosine kinases Src and ABL. It exhibits significant activity in hindering cell proliferation and survival in various cancer cell lines, making it a valuable tool for cancer research. Its specificity for Src/ABL pathways allows for detailed investigations into their roles in oncogenic processes and therapeutic responses. -
c-Abl Inhibitor
Tyrosine kinase-IN-9 is a potent inhibitor of the c-Abl tyrosine kinase. This compound demonstrates significant biological activity in modulating signaling pathways associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. It serves as a valuable research tool for investigating the roles of c-Abl in cellular processes related to these conditions. -
BCR-ABL Inhibitor
BCR-ABL kinase-IN-3 is a potent inhibitor of the BCR-ABL fusion protein, a critical driver in the pathology of acute myeloid leukemia (AML). This compound exhibits significant biological activity in inhibiting the kinase activity, making it a valuable tool for research into therapeutic strategies targeting BCR-ABL-related malignancies. Its application spans the investigation of molecular mechanisms underlying leukemia and the development of innovative treatments for improved patient outcomes. -
BCR-ABL Inhibitor
BCR-ABL-IN-11 is a selective BCR-ABL inhibitor that exhibits significant anticancer activity in chronic myelogenous leukemia (CML) models. With an IC50 value of 129.61 μM in K562 cells, BCR-ABL-IN-11 is a useful tool for studying the molecular mechanisms underlying CML and for evaluating potential therapeutic strategies targeting this oncogenic fusion protein. Its efficacy makes it suitable for research applications focused on leukemia treatment and drug resistance mechanisms. -
FLT3 Inhibitor
MZH29 is a potent inhibitor targeting FLT3, demonstrating significant activity against both wild-type and various mutant forms, including FLT3-ITD, FLT3-D835H/Y/V, and FLT3-K663Q. Notably, MZH29 effectively inhibits the FLT3-ITD/F691L mutation, a known drug resistance variant associated with AC220. This compound is valuable for research in the field of oncology, particularly for studies related to acute myeloid leukemia (AML). -
MER/FLT3 Inhibitor
UNC2025 hydrochloride is a potent ATP-competitive inhibitor targeting MER and FLT3, with IC50 values of 0.74 nM and 0.8 nM, respectively. It demonstrates over 45-fold selectivity for MERTK compared to Axl, exhibiting an IC50 of 122 nM and Ki of 13.3 nM. Its exceptional pharmacokinetic properties and ability to cross the blood-brain barrier make UNC2025 hydrochloride a valuable tool for investigating acute leukemia and related hematological conditions. -
CDK9/FLT3 Inhibitor
CDDD11-8 is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9) and FLT3-ITD, exhibiting Ki values of 8 nM and 13 nM, respectively. This compound effectively reduces the proliferation of leukemia cell lines, particularly those associated with the FLT3-ITD mutation. CDDD11-8 serves as a valuable tool for research into targeted therapies for hematological malignancies, specifically in the study of cell cycle regulation and tyrosine kinase signaling pathways. -
FLT3 Inhibitor
FLT3-IN-17 is a potent FLT3 inhibitor, effectively targeting FLT3 mutants with an IC50 of less than 0.5 nM for the D835Y variant. Additionally, it exhibits inhibitory effects on focal adhesion kinase (FAK), with an IC50 value of 12 nM. This compound is valuable for research into cancer biology, particularly in the context of FLT3-driven malignancies and related pathways. -
FLT3/AURKA Inhibitor
BPR1K871 is a potent dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively. This compound demonstrates significant anti-cancer activity and is suitable for preclinical development in oncology research. Its selective inhibition of these kinases makes it a valuable tool for studying FLT3 and AURKA-related signaling pathways in cancer. -
FLT3 Inhibitor
3-Hydroxy Midostaurin is an effective inhibitor of FMS-like tyrosine kinase-3 (FLT3), demonstrating autophosphorylation inhibition with IC50 values of approximately 132 nM in culture medium and 9.8 μM in plasma. This compound serves as a metabolite of PKC412 and exhibits greater cytotoxicity, albeit with reduced selectivity compared to its parent compound. It is particularly relevant in research focusing on hematological malignancies and FLT3-related signaling pathways. -
FLT3 Inhibitor
FLT3-IN-6 is a potent and selective FLT3-ITD inhibitor, demonstrating an IC50 of 1.336 nM. This compound effectively inhibits the mutated form of FLT3, making it a valuable tool in the study of hematological malignancies. Its specificity allows for precise exploration of FLT3-related pathways and potential therapeutic applications in cancer research. -
Dual FLT3/CHK1 Inhibitor
FLT3/CHK1-IN-1 is a dual inhibitor targeting both FLT3 and CHK1, demonstrating significant selectivity for c-KIT over other kinases. With an IC50 value of 58.4 μM, it shows reduced affinity for the hERG channel, minimizing potential cardiac side effects. FLT3/CHK1-IN-1 has exhibited efficacy in inhibiting tumor growth in mouse xenotransplantation models with MV-4-11 cells, making it a valuable tool for cancer research and therapeutic development. -
ITD-FLT3 Inhibitor
GTP-14564 is a selective inhibitor of the internal tandem duplication (ITD) variant of the FLT3 receptor tyrosine kinase. This compound effectively suppresses ligand-dependent proliferation of Ba/F3 leukemia cells, providing a valuable tool for the investigation of FLT3-related hematological malignancies. Its specificity may facilitate studies focused on the molecular mechanisms underlying FLT3-driven oncogenesis and therapeutic responses in leukemia. -
FLT3 Inhibitor
OTS447 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibiting an IC50 value of 21 nM. This compound is primarily utilized in research focused on hematological malignancies, particularly acute myeloid leukemia (AML), where aberrant FLT3 signaling is implicated. OTS447 serves as a valuable tool in studies investigating FLT3-related pathways and potential therapeutic strategies targeting FLT3 mutations. -
FLT3 Inhibitor
Crenolanib benzenesulfonate is a potent and selective inhibitor of FLT3, including both wild-type and mutant isoforms, as well as PDGFRα and PDGFRβ. With dissociation constants (Kd) of 0.74 nM for FLT3 and 2.1 nM/3.2 nM for PDGFRα/β, it exhibits strong biological activity. This compound is primarily utilized in research applications focused on hematological malignancies and other cancers driven by aberrant receptor tyrosine kinase signaling pathways. -
PDGFRβ/B-Raf Inhibitor
KG5 is an orally active dual inhibitor targeting PDGFRβ and B-Raf through allosteric mechanisms. It also exhibits inhibitory effects on Flt3, KIT, and c-Raf. KG5 demonstrates significant anticancer and antiangiogenic activities, making it a valuable reagent for research in cancer therapy and angiogenesis studies. -
FLT3 Inhibitor
FLT3-IN-16 is a highly effective FLT3 inhibitor, exhibiting an IC50 value of 1.1 μM. This compound plays a critical role in the study of acute myeloid leukemia (AML), facilitating research into therapeutic strategies targeting FLT3 signaling pathways. FLT3-IN-16 is essential for investigating the molecular mechanisms underlying AML and evaluating the efficacy of FLT3-targeted treatments. -
FLT3 Inhibitor
FLT3-IN-10 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), a key regulator in hematopoiesis and a pivotal target in certain leukemias. This compound exhibits significant activity against FLT3-mutated acute myeloid leukemia (AML), making it a valuable tool for research into targeted therapies. Its application in preclinical studies can aid in the understanding of FLT3's role in oncogenesis and in evaluating potential therapeutic strategies for FLT3-driven malignancies. -
FLT3/CDK5 Inhibitor
AMG 925 (HCl) is a potent dual inhibitor targeting FLT3 and CDK5, demonstrating IC50 values of 2±1 nM and 3±1 nM, respectively. This compound exhibits selectivity for these kinases, making it a valuable tool for research into hematological malignancies and cancer progression. Its oral bioavailability further enhances its utility in preclinical studies investigating therapeutic interventions for FLT3-driven malignancies and CDK5-associated diseases. -
FLT3 Inhibitor
FLT3-IN-19 is a potent and selective inhibitor of the FLT3 receptor tyrosine kinase, exhibiting an IC50 of 0.213 nM. This compound is primarily utilized in the research of acute myeloid leukemia (AML), facilitating studies on FLT3-dependent signaling pathways and potential therapeutic interventions. Its high specificity makes it an invaluable tool for understanding the molecular mechanisms underlying FLT3-driven malignancies. -
FLT3/Haspin Inhibitor
HSK205 is a potent dual inhibitor of FLT3 and Haspin, exhibiting an IC50 of 0.187 nM for FLT3. This compound demonstrates significant antitumor activity, making it a valuable tool in cancer research. Its dual targeting provides insights into the therapeutic potential for FLT3-driven malignancies and the role of Haspin in cell cycle regulation. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-3 is a highly effective inhibitor of PDGFRα and FLT3, exhibiting IC50 values of 0.153 μM and 0.004 μM, respectively. This compound serves as a valuable tool in the investigation of acute myeloid leukemia and chronic eosinophilic leukemia. Its potent inhibitory activity against key receptors makes it a significant candidate for related biomedical research applications. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-3 is a highly selective inhibitor targeting FLT3 internal tandem duplications (FLT3-ITD), demonstrating potent activity with IC50 values of 0.3 nM for FLT3D835Y, 0.4 nM for FLT3, and 0.9 nM for FLT3-ITD. This compound effectively inhibits FLT3 phosphorylation and exhibits significant antiproliferative effects against acute myeloid leukemia cell lines. It serves as a valuable tool in research aimed at understanding and developing therapies for FLT3-ITD associated malignancies. -
FLT3/IRAK4 Inhibitor
Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor that demonstrates significant antitumor activity. It is particularly relevant for research involving myeloid leukemia, where it may offer insights into therapeutic strategies targeting these pathways. Its unique mechanism of action makes it a valuable tool for investigating the roles of FLT3 and IRAK4 in cancer biology. -
PROTAC FLT3-ITD Degrader
PF15 is a PROTAC designed to target FLT3 kinase through its ligands linked with CRBN. This highly selective FLT3-ITD degrader exhibits a DC50 of 76.7 nM, effectively inhibiting the proliferation of FLT3-ITD-positive cells. PF15 down-regulates the phosphorylation of FLT3 and STAT5, demonstrating significant anti-tumor activity in mouse models, making it a valuable tool for leukemia research. -
Flt3 Inhibitor
D-65476 is a selective inhibitor of the Flt3 receptor tyrosine kinase, primarily acting in the absence of IL-3. It effectively suppresses the proliferation of TEL-Flt3 transfected BA/F3 cells, demonstrating an IC50 value of 0.2 μM. This compound is a valuable tool for exploring Flt3-driven leukemias and related therapeutic strategies. -
FLT3 Inhibitor
LT-850-166 is a potent inhibitor of FLT3, a receptor tyrosine kinase involved in hematopoiesis and leukemogenesis. It effectively targets various FLT3 mutations, demonstrating significant potential in the treatment of acute myeloid leukemia (AML) and other FLT3-driven malignancies. This compound serves as a valuable tool for research applications focused on understanding FLT3 signaling pathways and the development of targeted cancer therapies. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-2 is a selective inhibitor of FLT3 internal tandem duplications (FLT3-ITD), exhibiting IC50 values of 0.3 nM for FLT3D835Y, 0.4 nM for FLT3, and 1.0 nM for FLT3-ITD. This compound effectively blocks FLT3 phosphorylation and demonstrates robust antiproliferative effects on acute myeloid leukemia cell lines. It is a valuable tool for research into targeted therapies for leukemia and related disorders. -
FLT3/ITD Mutation Inhibitor
HP1328 is a potent inhibitor of the FLT3 receptor tyrosine kinase specifically targeting the FLT3/ITD mutation. This benzoimidazole scaffold-based compound demonstrates significant efficacy in reducing leukemia burden and prolonging survival in murine models of FLT3/ITD leukemia. HP1328 is valuable for research focused on targeted therapies for acute myeloid leukemia and advancing understanding of FLT3-related pathophysiology. -
FLT3 Inhibitor
FLT3-IN-11 is a potent and selective inhibitor of FLT3 kinase, exhibiting IC50 values of 7.22 nM and 4.95 nM for wild-type FLT3 and the FLT3-D835Y mutant, respectively. This compound demonstrates over 1000-fold selectivity for FLT3 compared to c-KIT. FLT3-IN-11 shows significant anti-acute myeloid leukemia (AML) activity, with an IC50 of 3.2 nM in MV4-11 cell assays, making it a valuable tool for research in AML therapeutics. -
FLT3 Inhibitor
FLT3-IN-32 TFA is a selective inhibitor of FLT3, targeting both FLT3-ITD and FLT3-D835Y with IC50 values of 2.40 nM and 3.83 nM, respectively. This compound effectively inhibits the proliferation and survival of human MV4-11 cells, demonstrating an IC50 of 0.07 nM. FLT3-IN-32 TFA is valuable for research focused on acute myeloid leukemia (AML), providing insights into targeted therapeutic strategies. -
FLT3 Inhibitor
MolPort-002-705-878 is a selective inhibitor of FMS-like tyrosine kinase 3 (FLT3) with a binding affinity of -11.33 kcal/mol. It effectively inhibits the proliferation of FLT3-mutated acute myeloid leukemia (AML) cells, making it a valuable tool for research in this domain. This compound holds potential for advancing studies focused on FLT3-mutated AML therapies. -
FLT3 Inhibitor
LT-540-717 is a potent inhibitor of the FLT3 receptor, exhibiting an IC50 of 0.62 nM. It demonstrates significant antiproliferative activity against cells harboring various acquired FLT3 mutations, including FLT3 ITD, D835V, F691L, and D835Y. Due to its selective inhibition of FLT3, LT-540-717 is a valuable candidate for research focused on acute myeloid leukemia (AML) treatment strategies. -
Mer/Flt3 Tyrosine Kinase Inhibitor
UNC1666 is an ATP-competitive dual-target inhibitor of the Mer and Flt3 tyrosine kinases, exhibiting potent inhibition with IC50 values of 0.55 nM and 0.69 nM, and Ki values of 0.16 nM and 0.67 nM, respectively. This compound effectively inhibits the kinase activities of Mer and Flt3, leading to decreased phosphorylation levels and suppression of downstream pro-survival signaling pathways such as Erk1/2, Akt, and Stat. Additionally, UNC1666 promotes apoptosis and reduces colony formation in acute myeloid leukemia cells, making it a valuable tool for research focused on this malignancy. -
FLT3/FLT3-ITD Inhibitor
FLT3/ITD-IN-5 is a potent inhibitor of FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is designed for use in cancer research, providing valuable insights into therapies targeting FLT3 mutations commonly found in acute myeloid leukemia (AML). Its high selectivity makes it an essential tool for studying FLT3 signaling pathways and developing targeted treatments. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-4 is a selective inhibitor of FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD), exhibiting an IC50 of 2.3 nM. This compound demonstrates potent biological activity against FLT3-ITD mutations, making it valuable for research in acute myeloid leukemia. FLT3/ITD-IN-4 is ideal for studies exploring targeted therapies and the underlying mechanisms of FLT3-mediated signaling. -
FLT3 Receptor Antagonist
BDT001 is a selective FLT3 receptor antagonist that inhibits the signaling pathways associated with FLT3 activation. This compound demonstrates significant potential in research applications focused on pain disorders, cancer, and autoimmune diseases by modulating the activity of FLT3, a receptor implicated in cellular proliferation and survival. BDT001 serves as a valuable tool for investigating therapeutic strategies targeting FLT3-related pathologies. -
BTK/FLT3 Inhibitor
RSH-7 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and Fms-like tyrosine kinase 3 (FLT3), exhibiting IC50 values of 47 nM and 12 nM, respectively. This compound induces apoptosis and demonstrates significant antiproliferative activity. By inhibiting BTK and FLT3 signaling pathways, RSH-7 is a valuable tool for research in oncology and targeted therapies for hematological malignancies. -
FLT3 Inhibitor
FLT3-IN-26 is a potent FLT3 inhibitor with a pIC50 value of 7.367. This compound demonstrates significant biological activity against FLT3, making it a valuable tool for investigating acute myeloid leukemia. Its specificity and efficacy facilitate research into targeted therapies for this malignancy. -
FLT3 Inhibitor
FLT3-IN-12 is a selective and orally bioavailable inhibitor of the FLT3 kinase, demonstrating IC50 values of 1.48 nM for FLT3-WT and 2.87 nM for the FLT3-D835Y mutant. This compound exhibits exceptional selectivity over c-KIT, surpassing 1000-fold. Additionally, FLT3-IN-12 showcases potent anti-acute myeloid leukemia (AML) activity, with an IC50 of 0.75 nM against the MV4-11 cell line, making it a valuable tool for the study of FLT3-driven malignancies and potential therapeutic applications in AML. -
FLT3 Inhibitor
FLT3-IN-15 is a potent and orally bioavailable inhibitor of the FLT3 receptor, exhibiting IC50 values of 0.87 nM for FLT3 and 0.32 nM for the FLT3/D835Y mutant. This compound is primarily utilized in research related to acute myeloid leukemia, providing insights into the therapeutic potential of targeting aberrant FLT3 signaling pathways in cancer treatment. -
FLT3 inhibitor
FLT3-IN-23 is a potent inhibitor of the Fms-like tyrosine kinase 3 (FLT3), exhibiting an IC50 value of 7.42 nM. It demonstrates significant antiproliferative activity against BaF3 cells harboring multiple FLT3 tyrosine kinase domain (TKD) and internal tandem duplication (ITD) mutations. This compound serves as a valuable tool for research in targeted therapies for FLT3-mutant leukemias. -
FLT3/D835Y Inhibitor
FLT3/D835Y-IN-1 is a potent and selective inhibitor targeting FLT3 and the FLT3/D835Y mutant with IC50 values of 0.26 nM and 0.18 nM, respectively. This orally active compound demonstrates significant inhibition of tumor growth and exhibits anticancer efficacy, making it a valuable tool for research into acute myeloid leukemia (AML). FLT3/D835Y-IN-1 provides a targeted approach for studying the effects of FLT3 mutations in cellular and animal models of AML. -
FLT3 Inhibitor
CHEMBL4444839 is a potent FLT3 inhibitor that plays a crucial role in the study of acute myeloid leukemia (AML). Its ability to selectively target FLT3 makes it a valuable tool for investigating the molecular mechanisms of AML and developing potential therapeutic strategies. Researchers can leverage CHEMBL4444839 to explore the effects of FLT3 inhibition on cell proliferation and survival in AML models. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-1 is a selective inhibitor of the platelet-derived growth factor receptor alpha (PDGFRα) and the Fms-like tyrosine kinase 3 (FLT3), demonstrating IC50 values of 0.036 μM and 0.003 μM, respectively. This compound is particularly relevant for investigations into acute myeloid leukemia (AML) and chronic eosinophilic leukemia (CEL), providing a valuable tool for exploring therapeutic strategies targeting these malignancies. Researchers utilizing PDGFRα/FLT3-ITD-IN-1 can gain insights into the molecular mechanisms underlying these hematological disorders. -
FLT3 Inhibitor
FLT3-IN-18 is a highly selective inhibitor of FLT3, exhibiting an IC50 value of 0.003 μM. This compound effectively induces apoptosis and enforces G1 phase cell cycle arrest in FLT3-positive cells. Additionally, FLT3-IN-18 inhibits both FLT3 and STAT5 phosphorylation, making it a valuable tool for investigating the signaling pathways involved in acute myeloid leukemia (AML). Its potency and specificity position FLT3-IN-18 as a crucial reagent for researching FLT3-driven malignancies.
